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INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune dis-
ease that can have various multisystem manifestations.1 Among 
the numerous manifestations of SLE is lupus nephritis (LN). 
Occurring in 40–75% of patients with SLE, LN is associated with 
a poor prognosis in these patients.2 LN may present with pro-
teinuria, hematuria, active urinary sediment, or decreased renal 
function,3 and can progress to end-stage renal disease (ESRD).4 
Although LN can develop at various time points during the dis-
ease course of SLE, it usually develops within 5 years of SLE on-
set5,6 and more commonly at the onset of SLE (in approximately 
50% of cases).7
The course and outcomes of LN are determined by an inter-
play of demographic, histopathological, and laboratory factors.8 
Meanwhile, several studies have investigated whether the on-
set time of LN can affect the clinical presentations and outcomes 
of LN patients.9,10 Varela, et al.9 showed that the renal presenta-
tions and histopathologic patterns did not differ between ear-
ly-onset LN (LN that developed within ≤5 years after SLE diag-
nosis) and delayed LN (LN that developed ≥5 years after SLE 
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diagnosis). Another study reported worse renal outcomes in 
delayed-onset LN (mean interval between SLE diagnosis and 
LN diagnosis: 8.9 years) than in initial-onset LN (LN diagnosed 
at the onset of SLE).10 However, to date, data are lacking on 
whether the clinical characteristics of renal disease differ be-
tween initial-onset LN and early-onset LN, which accounts for 
the majority of LN cases. Here, we aimed to compare clinical 




Patients in whom LN was diagnosed using renal biopsy between 
July 2006 and December 2018 at two tertiary referral hospitals 
in Seoul, Korea were retrospectively selected for inclusion into 
this study. As our aim was to compare initial-onset LN and ear-
ly-onset LN, which was not previously studied, patients who 
developed LN after >5 years of SLE diagnosis were excluded. 
All patients met the 1997 American College of Rheumatology 
classification criteria for SLE.11 For comparison, patients were 
categorized into two groups according to the onset time of LN: 
those who initially developed LN at the time of SLE onset (initial-
onset LN group) and those who developed LN within 5 years 
after SLE onset (early-onset LN group). Patients who had sus-
picious findings of nephritis (elevated creatinine, proteinuria, 
hematuria, pyuria, and urinary cast) at the time of SLE diagno-
sis and who underwent renal biopsy accordingly were catego-
rized as initial-onset LN. Patients who did not have suspicious 
findings of nephritis and did not undergo renal biopsy at the 
time of SLE diagnosis, but developed suspicious findings of ne-
phritis during follow up were categorized as early-onset LN. 
The patients in the early-onset LN group underwent renal bi-
opsy at the time when suspicious findings of nephritis devel-
oped during follow up.
This study was approved by the Institutional Review Board 
of Gangnam Severance Hospital (IRB No: 3-2019-0072). Owing 
to the retrospective nature of this study, the requirement for 
informed consent was waived.
Clinical parameters and medications
We reviewed the following information recorded at the diag-
nosis of LN: age, sex, time from diagnosis of SLE to diagnosis 
of LN, presence of hypertension and diabetes mellitus, serum 
albumin and creatinine levels, estimated glomerular filtration 
rate (eGFR), antibodies to extractable nuclear antigens, lupus 
anticoagulant, anti-β2 glycoprotein I antibody, anti-cardiolipin 
antibody, C3, C4, urinalysis results, urine protein/creatinine 
ratio (UPCR), presence of SLE manifestations other than renal 
disease, SLE Disease Activity Index (SLEDAI),12 International 
Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 
classification,13 activity index, chronicity index, tubulointersti-
tial inflammation, tubular atrophy, interstitial fibrosis, and glo-
merulosclerosis. For analysis, tubulointerstitial inflammation, 
tubular atrophy, and interstitial fibrosis were categorized into 
dichotomous variables (none-to-mild: <25% of the acreage of 
interstitium affected vs. moderate-to-severe: >25% of the acre-
age of interstitium affected).14 The severity of glomerulosclero-
sis was assessed as the proportion of sclerotic glomeruli to to-
tal glomeruli.
Medications prescribed during the observation period were 
also reviewed. Patients with proliferative LN (class III and class 
IV) and membranous LN (class V) with nephrotic range pro-
teinuria received immunosuppressants. For induction thera-
py, patients received mycophenolate mofetil (2–3 g/day)15 or 
cyclophosphamide according to the Euro-Lupus Nephritis regi-
men16 or the National Institutes of Health protocol17 with mod-
erate-to-high dose glucocorticoid. After 4 weeks, glucocorticoid 
dosages were tapered according to the treating physicians’ de-
cision. Patients who failed to respond were switched from my-
cophenolate mofetil to cyclophosphamide (and vice versa) or 
received rituximab. For maintenance therapy, mycophenolate 
mofetil, azathioprine, or tacrolimus with low-dose glucocorti-
coid (≤7.5 mg prednisolone or its equivalent) was used.
Renal outcome
For the comparison of renal outcomes between the two groups, 
achievement of a complete renal response (UPCR <500 mg/g 
and normal GFR or within 10% of normal GFR if previously ab-
normal)18 at 6 months after the initiation of induction therapy, 
occurrence of relapse, and progression to chronic kidney dis-
ease (CKD) or ESRD were evaluated. Relapse was defined as a 
>25% decline in GFR, a 50% or more increase in proteinuria, or 
active urine sediment characterized by >5 red blood cell/high-
power field and/or cellular casts.19 CKD was defined as GFR 
<60 mL/min/1.73 m2 for ≥3 months,20 and ESRD was defined 
as requiring renal replacement therapy with GFR <15 mL/
min/1.73 m2.20 The patients were retrospectively reviewed un-
til they developed CKD or ESRD or until the last hospital visit, 
whichever occurred first.
Statistical analysis
Data are presented as means (±standard deviations) or medians 
(interquartile range) for normal distributing or non-normal dis-
tributing continuous variables, respectively, and numbers (%) 
for categorical variables. For the comparisons between groups, 
Student’s t-test or the Mann-Whitney test was used for contin-
uous variables, and Fisher’s exact test (or chi-square test when 
appropriate) was used for categorical variables. The relapse-
free survival rates and CKD- or ESRD-free survival rates were 
analyzed using Kaplan-Meier analysis and were compared us-
ing a log-rank test. We used Cox regression to estimate hazard 
ratios (HRs) for renal relapse and progression to CKD or ESRD, 
with the onset time of LN as the variable of interest. We initial-
ly performed an univariable analysis, and then performed mul-
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tivariable analyses adjusted for potential confounders. Multi-
variable models first included renal histologic parameters (ISN/
RPS class, activity index, and chronicity index) (model 1), fol-
lowed by additional adjustment for other renal parameters 
(GFR, UPCR, and hematuria) (model 2), and use of hydroxy-
chloroquine (HCQ) and immunosuppressive agents (model 
3). A value of p<0.05 was considered statistically significant. 
All analyses were conducted using SPSS software (SPSS ver-
sion 25.0; IBM Corporation, Armonk, NY, USA).
RESULTS
Characteristics at the time of LN diagnosis
A total of 179 patients with biopsy-confirmed LN, who met the 
American College of Rheumatology classification criteria for 
SLE,11 were identified. Forty-three patients in whom LN devel-
oped at >5 years after the diagnosis of SLE were excluded, and 
the remaining 136 patients were included for analysis. Of these 
136 patients, 92 (67.6%) patients were categorized as the initial-
onset LN group, and the other 44 (32.4%) patients were catego-
rized as the early-onset LN group. Patients in the early-onset 
LN group developed LN at a median of 25.1 (10.8–38.4) months 
after the diagnosis of SLE. The median observation period was 
59.5 (21.3–94.3) months from the diagnosis of LN [Initial-onset 
LN group: 43.7 (15.5–88.8) months, and early-onset LN group: 
80.7 (45.4–110.1) months]. A comparison of clinical character-
istics at diagnosis of LN between the initial-onset and early-on-
set LN groups is shown in Table 1. Age (p=0.714), sex distribu-
tion (p=0.226), and the proportion of patients with hypertension 
(p=0.101) and diabetes mellitus (p=0.437) did not differ between 
groups. There were no significant differences in autoantibody 
profile between the two groups. C3 level [35.1 (24.6–56.8) mg/
dL vs. 52.7 (41.4–75.4) mg/dL, p<0.001], C4 level [5.2 (2.6–9.3) 
mg/dL vs. 11.0 (5.2–18.0) mg/dL, p=0.001] and serum albumin 
level [2.6 (2.2–3.2) g/dL vs. 3.3 (2.5–3.6) g/dL, p=0.005] were 
lower in the initial-onset LN group. In terms of SLE manifesta-
tions other than LN, serositis [20 (21.7%) vs. 1 (2.3%), p=0.003] 
and hematologic manifestations [49 (53.3%) vs. 12 (27.3%), 
p=0.004] were more common in the initial-onset LN group. Fur-
ther, SLEDAI (17.6±5.8 vs. 14.5±6.2, p=0.005) was significantly 
higher in the initial-onset LN group. In comparison of renal 
parameters, patients in the initial-onset LN group more com-
monly had eGFR <60 mL/min/1.73 m2 [32 (34.8%) vs. 5 (11.4%), 
p=0.004], had higher UPCR [4626.1 (2180.0–6788.3) mg/g vs. 
2140.0 (1265.0–5168.5) mg/g, p=0.006], and more commonly 
had microscopic hematuria [68 (73.9%) vs. 24 (54.5%), p=0.024]. 
There were no significant differences in histologic data be-
tween the two groups, except the higher prevalence of class IV 
LN (54.3% vs. 34.1%, p=0.027) and lower chronicity index val-
ues [1.0 (0.0–2.0) vs. 2.0 (1.0–3.0), p=0.028] in the initial-onset 
LN group.
Comparison of treatment and renal outcomes 
according to the onset of LN
Patients who did not receive immunosuppressive therapy for 
LN (3 patients with class I LN, 4 patients with class II LN, and 
7 patients with class V LN) were excluded from this analysis 
because the treatment and renal outcomes in these patients 
could not be determined. Eighty-six and 36 patients remained 
in the initial-onset LN and early-onset LN groups, respectively. 
In the induction phase, the use of HCQ (p=0.091), mycophe-
nolate mofetil (p=0.327), cyclophosphamide (p=0.266), and 
rituximab (p>0.999) did not differ between the two groups. 
However, patients in the initial-onset LN group received high-
er cumulative doses of glucocorticoid during the first 6 months 
(6548.4±2826.8 mg vs. 5098.4±2649.8 mg, p=0.010). After 6 
months of induction treatment, a complete renal response was 
less commonly achieved in the initial-onset LN group [45 (52.3%) 
vs. 26 (72.2%), p=0.042].
For the comparison of the medications used during the main-
tenance phase, patients who were refractory to induction ther-
apy (6 patients in the initial-onset LN group and 1 patient in 
the early-onset LN group) were excluded, as the maintenance 
phase could not be determined in these patients. No significant 
differences were observed in the medications used (HCQ, p= 
0.070; mycophenolate mofetil, p>0.999; azathioprine, p=0.227; 
tacrolimus, p=0.765) in the maintenance phase. The two groups 
did not differ in regards to the use of angiotensin converting 
enzyme inhibitor or angiotensin II receptor blocker [71 (82.6%) 
vs. 32 (88.9%), p=0.379].
The occurrence of relapse after remission was more com-
mon in the initial-onset LN group [37 (46.3%) vs. 9 (25.7%), p= 
0.039]. Moreover, the incidence of progression to CKD or ESRD 
was higher [21 (24.4%) vs. 3 (8.3%), p=0.042] in the initial-onset 
LN group (Table 2). Kaplan-Meier analysis of the two groups 
revealed significantly lower relapse-free survival (p=0.005) 
(Fig. 1) and CKD- or ESRD-free survival (p=0.023) (Fig. 2) in 
the initial-onset LN group.
Onset time of LN and risk of renal relapse and 
progression to CKD or ESRD
Table 3 shows the risk of renal relapse and progression to CKD 
or ESRD in the initial-onset LN group, compared with the early-
onset LN group. In univariable analysis, initial-onset LN posed 
a higher risk of renal relapse [unadjusted HR 2.73, 95% confi-
dence interval (CI) 1.32–5.69, p=0.007] and progression to CKD/
ESRD (unadjusted HR 4.20, 95% CI 1.25–14.13, p=0.020). After 
adjusting for renal histologic parameters (multivariable analy-
sis model 1), initial-onset LN was associated with higher risks 
of renal relapse (adjusted HR 3.47, 95% CI 1.56–7.71, p=0.002) 
and progression to CKD/ESRD (adjusted HR 7.54, 95% CI 1.94–
29.38, p=0.004). With additional adjustment for other renal 
parameters (multivariable analysis model 2), initial-onset LN 
was still significantly associated with higher risks of renal re-
lapse (adjusted HR 3.12, 95% CI 1.40–6.96, p=0.006) and pro-
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Table 1. Comparison of Baseline Characteristics According to the Onset of LN
Initial-onset LN (n=92) Early-onset LN (n=44) p value
Age (yr) 35.7 (±16.5) 36.8 (±13.8) 0.714
Female sex 80 (87.0) 42 (95.5) 0.226
Hypertension 24 (26.1) 6 (13.6) 0.101
Diabetes mellitus 7 (7.6) 1 (2.3) 0.437
Serology
Anti-Sm Ab 37 (40.2) 22 (50.0) 0.282
Anti-Ro Ab 54 (58.7) 30 (68.2) 0.287
Anti-La Ab 21 (22.8) 15 (34.1) 0.164
Anti-U1RNP Ab 50 (54.3) 26 (59.1) 0.602
Anti-dsDNA Ab, median (IQR), IU/mL 160.0 (19.3–379.0) 240.7 (4.8–380.0) 0.786
Lupus anticoagulant 16 (17.4) 8 (18.2) 0.910
Anti-β2 glycoprotein I Ab 14 (15.2) 5 (11.4) 0.544
Anti-cardiolipin Ab 24 (26.1) 13 (29.5) 0.672
C3, median (IQR), mg/dL 35.1 (24.6–56.8) 52.7 (41.4–75.4) <0.001
C4, median (IQR), mg/dL 5.2 (2.6–9.3) 11.0 (5.2–18.0) 0.001
Serum albumin, median (IQR), g/dL 2.6 (2.2–3.2) 3.3 (2.5–3.6) 0.005
Other SLE manifestations
Mucocutaneous 28 (30.4) 7 (15.9) 0.070
Musculoskeletal 28 (30.4) 13 (29.5) 0.916
Neuropsychiatric 7 (7.6) 3 (6.8) >0.999
Serositis 20 (21.7) 1 (2.3) 0.003
Hematologic 49 (53.3) 12 (27.3) 0.004
SLEDAI 17.6 (±5.8) 14.5 (±6.2) 0.005
Renal parameters
Serum Cr, median (IQR), mg/dL 0.90 (0.65–1.33) 0.78 (0.64–1.00) 0.113
eGFR, median (IQR), mL/min/1.73 m2 84.0 (50.0–119.0) 100.0 (74.3–116.8) 0.119
eGFR <60 mL/min/1.73 m2 32 (34.8) 5 (11.4) 0.004
Urine PCR, median (IQR), mg/g 4626.1 (2180.0–6788.3) 2410.0 (1265.0–5168.5) 0.006
Urine RBC ≥5/HPF 68 (73.9) 24 (54.5) 0.024
Urine WBC ≥5/HPF 52 (56.5) 22 (50.0) 0.475
Urine cast 18 (19.6) 5 (11.4) 0.233
ISN/RPS class
I 2 (2.2) 1 (2.3) >0.999
II 2 (2.2) 2 (4.5) 0.595
III 18 (19.6) 12 (27.3) 0.311
III+V 6 (6.5) 4 (9.1) 0.727
IV 50 (54.3) 15 (34.1) 0.027
IV+V 6 (6.5) 3 (6.8) >0.999
V 8 (8.7) 7 (15.9) 0.246
Activity index, mean median (IQR) 7.5 (4.0–10.3) 6.0 (1.0–10.0) 0.404
Chronicity index, median (IQR) 1.0 (0.0–2.0) 2.0 (1.0–3.0) 0.028
Moderate-to-severe TII 14 (15.2) 4 (9.1) 0.324
Moderate-to-severe TA/IF 3 (3.3) 3 (6.8) 0.388
Glomerulosclerosis, median (IQR) 4.6 (0.0–14.9) 9.1 (0.0–28.6) 0.180
LN, lupus nephritis; Ab, antibody; anti-dsDNA, anti-double-stranded DNA; SLE, systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease 
Activity Index; Cr, creatinine; eGFR, estimated glomerular filtration rate; PCR, protein/creatinine ratio; RBC, red blood cell; HPF, high-power field; WBC, white 
blood cell; ISN/RPS, International Society of Nephrology/Renal Pathology Society; TII, tubulointerstitial inflammation; TA, tubular atrophy; IF, interstitial fibrosis; 
SD, standard deviation; IQR, interquartile range.
Data are presented as mean±standard deviation or n (%).
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gression to CKD/ESRD (adjusted HR 4.39, 95% CI 1.07–17.96, 
p=0.040). We obtained similar results after further adjustment 
for use of HCQ and immunosuppressive agents (multivariable 
analysis model 3).
DISCUSSION
In this study, we found that patients who initially developed LN 
at the time of SLE onset had more severe renal manifestations 
and faced a higher risk of worse renal outcomes than those who 
developed LN within 5 years after the diagnosis of SLE. To our 
knowledge, this is the first study to show differences in renal 
presentation and renal outcomes between initial-onset LN and 
early-onset LN.
A previous study reported no differences in pattern of glomer-
ular lesions between early-onset LN and delayed LN,9 whereas 
a recent study reported a higher prevalence of class IV LN in 
Table 2. Comparison of Treatment and Renal Outcomes According to the Onset of LN
Initial-onset LN (n=86) Early-onset LN (n=36) p value
Medication in the induction phase
HCQ 56 (65.1) 29 (80.6) 0.091
MMF 62 (72.1) 29 (80.6) 0.327
CYC 38 (44.2) 12 (33.3) 0.266
RTX 2 (2.3) 0 (0.0) >0.999
Glucocorticoid, mg* 6548.4 (±2826.8) 5098.4 (±2649.8) 0.010
Duration of induction phase, months 8.1 (±3.3) 7.8 (±3.9) 0.595
Complete renal response at 6 months 45 (52.3) 26 (72.2) 0.042
Refractory to induction therapy 6 (7.0) 1 (2.8) 0.672
Medication in the maintenance phase†
HCQ 53 (66.3) 29 (82.9) 0.070
MMF 74 (92.5) 32 (91.4) >0.999
AZA 8 (10.0) 7 (20.0) 0.227
TAC 18 (22.5) 7 (20.0) 0.765
ACE inhibitor or ARB 71 (82.6) 32 (88.9) 0.379
Relapse after remission† 37 (46.3) 9 (25.7) 0.039
Time from remission to relapse, median (IQR), months 20.2 (9.1–52.5) 41.3 (10.7–77.4) 0.354
Progression to CKD or ESRD 21 (24.4) 3 (8.3) 0.042
Time from LN to CKD or ESRD, median (IQR), months 11.3 (4.7–34.5) 29.8 (17.8–74.6) 0.315
LN, lupus nephritis; HCQ, hydroxychloroquine; MMF, mycophenolate mofetil; CYC, cyclophosphamide; RTX, rituximab; AZA, azathioprine; TAC, tacrolimus; ACE, 
angiotensin converting enzyme; ARB, angiotensin II receptor blocker; CKD, chronic kidney disease; ESRD, end-stage renal disease; SD, standard deviation; IQR, 
interquartile range.
Data are presented as mean±standard deviation or n (%).
*Cumulative dose of glucocorticoid during the first 6 months in the induction phase, †Patients refractory to induction therapy (n=7) were excluded.



































Fig. 2. Kaplan-Meier survival curves for CKD- or ESRD-free survival. LN, 
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early-onset LN than in delayed LN.21 Similar to this recent study, 
we observed differences in patterns of glomerular lesions be-
tween initial-onset LN and early-onset LN: the prevalence of 
class IV LN was higher in initial-onset LN than in early-onset 
LN. We also found that chronicity index values were significantly 
lower in the initial-onset LN group, although the difference in 
absolute values was only modest (median values of 1.0 and 2.0 
for initial-onset LN group and early-onset LN group, respective-
ly). The differences in histology, especially the higher prevalence 
of class IV LN, in the initial-onset LN might have contributed 
to the worse renal outcomes in the initial-onset LN group. How-
ever, in multivariable analysis model 1, wherein we adjusted for 
renal histologic parameters, a higher risk of worse renal out-
comes in the initial-onset LN group was observed. This suggests 
that the worse renal outcomes in the initial-onset LN group 
cannot be fully explained by differences in renal histology and 
that the disease course of LN may differ depending on the on-
set time of LN. Notably, achievement of a complete renal re-
sponse at 6 months after starting induction treatment, which is 
predictive of good long-term renal outcome,22 was less common 
in the initial-onset LN group. This might have attributed to the 
worse renal outcomes in the initial-onset LN group.
C3, C4, and serum albumin levels were significantly lower, 
and other SLE manifestations, including serositis and hemato-
logic manifestations, were more common in the initial-onset 
LN group, indicating higher systemic disease activity of SLE. 
Indeed, SLEDAI values were significantly higher in the initial-
onset LN group than in the early-onset LN group at the time of 
LN diagnosis. Considering that early-onset LN may develop in 
circumstances where systemic disease activity is relatively low, 
SLE patients without LN initially may benefit from careful re-
nal monitoring even when systemic disease activity is low.
The initial-onset LN group more commonly had GFR <60 
mL/min/1.73 m2 and hematuria, as well as higher amounts of 
proteinuria, at the time of LN diagnosis, suggesting more ag-
gressive renal presentation in this groups. This might be a re-
sult of lead time bias. That is, as the patients in the early-onset 
LN group were being followed for their SLE, they were on rou-
tine renal surveillance, which might have resulted in earlier 
detection and milder renal presentation. Furthermore, as the 
patients in the early-onset LN group were on treatment of SLE 
prior to the development of LN, this might also have contribut-
ed to the milder renal presentation in this group. To minimize 
confounding from lead time bias, we adjusted for renal param-
eters in multivariable analysis model 2, and the risks of renal 
relapse and progression to CKD or ESRD were higher in the ini-
tial-onset LN group. This suggests that the difference in renal 
outcomes between the initial-onset LN and early-onset LN 
groups was not likely the result of lead time bias. Furthermore, 
the association between initial-onset LN and worse renal out-
come remained statistically significant when additionally ad-
justing for the use of HCQ and immunosuppressive agents, 
which are other potential confounders. Nevertheless, the po-
tential mechanism underlying the difference in renal outcomes 
according to the onset time of LN is currently unclear and needs 
further investigation.
In a previous study comparing initial-onset LN and delayed-
onset LN (mean time from SLE to LN: 8.9 years), initial-onset LN 
had a better prognosis.10 More recently, another study compar-
ing LN that developed within 1 year from SLE diagnosis (defined 
as early-LN in that study) and delayed-onset LN (mean time 
from SLE to LN: 8.9 years) showed that early LN had better out-
comes.21 In our present study, the median time interval between 
SLE diagnosis and LN diagnosis in the early-onset LN group, 
which had more favorable renal outcomes than the initial-on-
set LN group, was 25.1 months (2.1 years). Taken together with 
the previous reports,10,21 we suspect that the renal prognosis of 
LN may differ depending on the onset time of LN diagnosis.
Our present study has several limitations. First, this was a ret-
rospective study. Unidentified confounders may exist, which 
stems from the retrospective design. Second, although we in-
cluded patients from two medical centers, all patients were Ko-
rean. Further studies with a larger number of patients from dif-
ferent ethnic populations may be helpful to confirm our results.
In summary, we showed that the renal characteristics and 
renal outcomes of LN may differ depending on its onset time. 








HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Renal relapse
Early-onset LN 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Initial-onset LN 2.73 (1.32–5.69) 0.007 3.47 (1.56–7.71) 0.002 3.12 (1.40–6.96) 0.006 3.56 (1.51–8.35) 0.004
Progression to CKD/ESRD
Early-onset LN 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Initial-onset LN 4.20 (1.25–14.13) 0.020 7.54 (1.94–29.38) 0.004 4.39 (1.07–17.96) 0.040 4.57 (1.03–20.17) 0.045
LN, lupus nephritis; CKD, chronic kidney disease; ESRD, end-stage renal disease; ISN/RPS, International Society of Nephrology/Renal Pathology Society (ISN/
RPS); GFR, glomerular filtration rate; UPCR, urine protein/creatinine ratio; HCQ, hydroxychloroquine; HR, hazard ratio; CI, confidence interval.
*Adjusted for ISN/RPS class, activity index, chronicity index, †Adjusted for ISN/RPS class, activity index, chronicity index, GFR, UPCR, hematuria, ‡Adjusted for 
ISN/RPS class, activity index, chronicity index, GFR, UPCR, hematuria, use of HCQ, and use of immunosuppressive agents.
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Patients who develop LN at the onset of SLE may have more 
severe renal presentations and may be at risk of worse renal 
outcomes than patients who develop LN within 5 years after 
SLE onset.
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